Myofibrillogenesis regulator 1 (MR-1): a potential therapeutic target for cancer and PNKD
Author:
Affiliation:
1. Key Laboratory of Antibiotic Bioengineering, Ministry of Health, Laboratory of Oncology, Institute of Medicinal Biotechnology, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, PR China
Funder
National Natural Science Foundation of China
National Mega-project for Innovative Drugs
National Key Research and Development Program of China
CAMS Innovation Fund for Medical Sciences
Publisher
Informa UK Limited
Subject
Pharmaceutical Science
Link
https://www.tandfonline.com/doi/pdf/10.1080/1061186X.2017.1401077
Reference34 articles.
1. Characterization of MR-1, a Novel Myofibrillogenesis Regulator in Human Muscle
2. The gene for paroxysmal non-kinesigenic dyskinesia encodes an enzyme in a stress response pathway
3. Translation initiation factor modifications and the regulation of protein synthesis in apoptotic cells
4. Aspirin inhibits the proliferation of human uterine leiomyoma cells by downregulation of K-Ras-p110α interaction
Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. A nonparametric framework for treatment effect modifier discovery in high dimensions;Journal of the Royal Statistical Society Series B: Statistical Methodology;2024-08-21
2. A prognostic risk model based on lactate metabolism and transport-related lncRNAs for gastric adenocarcinoma;Biomarkers;2024-04-17
3. Myofibrillogenesis Regulator‐1 Regulates the Ubiquitin Lysosomal Pathway of Notch3 Intracellular Domain Through E3 Ubiquitin‐Protein Ligase Itchy Homolog in the Metastasis of Non‐Small Cell Lung Cancer;Advanced Science;2024-02-11
4. ZC3H4 governs epithelial cell migration through ROCK/p-PYK2/p-MLC2 pathway in silica-induced pulmonary fibrosis;Environmental Toxicology and Pharmacology;2023-11
5. A novel lactate metabolism-related signature predicts prognosis and tumor immune microenvironment of breast cancer;Frontiers in Genetics;2022-09-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3